Tier 2 — strong
The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials
Inflammopharmacology
2022
30(3):1063-1077
Bibliography
- PubMed
- PMID 35352233
- PubMed Central
- PMC9135894
- Funding
- Reported funding sources: http://dx.doi.org/10.13039/100007847Natural Science Foundation of Jilin Province. Grant and funder-role details are in the publication.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Systematic review and meta-analysis |
|---|---|
| Model | Published human studies |
| Sample | 52 studies; 4616 patients |
| Intervention | Evidence synthesis; interventions and comparators vary across included studies |
| Duration | No new treatment; included-study durations vary |
| Endpoints | Pooled clinical or metabolic outcomes; Risk of bias and heterogeneity; Adverse-event reporting |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
